Key Performance
More- Earnings Score: 85
- Momentum Score: 31
- True Yield: N/A
- Financial Health Score: 63
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
Hims & Hers Health (NYSE: HIMS) faces a securities class action lawsuit following an FTC complaint alleging the company deceptively shared consumers' health data with third-party advertising platforms like Meta and Snap, and violated billing regulations by charging for prescriptions before medical consultations. The stock plunged 14.7% on July 29, 2026, erasing over $970 million in market value.
10/09/2026, 6:12 PM • GlobeNewswire
Rosen Law Firm has filed securities class action lawsuits against Hims & Hers Health, Duolingo, and Ardelyx. The Hims lawsuit alleges the company made false statements regarding data privacy practices, prescription charging procedures, and failed to disclose regulatory scrutiny and potential penalties. Investors who purchased securities during specified class periods are encouraged to join the litigation before the November 2, 2026 lead plaintiff deadline.
10/08/2026, 8:02 PM • GlobeNewswire
Hims & Hers Health faces a securities fraud class action lawsuit after the FTC alleged the telehealth provider shared consumers' sensitive health information with third-party advertising platforms while claiming privacy protection, and deceived users about billing and cancellation practices. The stock declined 14.73% on July 29, 2026, following the FTC announcement. Investors who purchased securities between August 4, 2025 and July 29, 2026 have until November 2, 2026 to file lead plaintiff applications.
10/06/2026, 9:52 PM • GlobeNewswire
Kahn Swick & Foti, LLC announces class action securities lawsuits against AEVEX Corp. and York Space Systems, Inc. for alleged fraud. AEVEX is accused of concealing a pre-arranged plan to prematurely override a 180-day lock-up agreement, allowing major shareholder Madison to sell shares and underwriters to collect additional fees. Investors who purchased shares during the class periods have until the specified deadlines to request lead plaintiff status.
10/06/2026, 9:37 PM • GlobeNewswire
Holzer & Holzer, LLC announced lead plaintiff deadlines for shareholder class action lawsuits against Unicycive Therapeutics, Hims & Hers Health, and Beta Bionics. The lawsuits allege materially false statements and non-disclosure of material facts regarding regulatory risks, deceptive billing practices, data sharing, and device safety issues. Investors who purchased shares during specified periods and suffered losses are encouraged to seek lead plaintiff status by November 2-3, 2026.
10/06/2026, 7:00 AM • GlobeNewswire
A class action lawsuit has been filed against Hims & Hers Health, Inc. alleging securities fraud. The complaint claims the company made false statements about consumer health data privacy, charged patients for prescriptions before medical consultations, and failed to disclose regulatory risks and potential penalties. Investors who purchased Hims securities between August 4, 2025 and July 29, 2026 may be eligible to join the case.
10/05/2026, 11:00 PM • GlobeNewswire
Rosen Law Firm is soliciting investors who purchased securities of Hims & Hers Health, Inc. between August 4, 2025 and July 29, 2026 to join a class action lawsuit. The lawsuit alleges that Hims made materially false statements regarding data privacy practices, prescription charging procedures, and regulatory compliance, which subjected the company to potential fees and penalties.
10/05/2026, 8:44 PM • GlobeNewswire
A securities class action lawsuit has been filed against Hims & Hers Health, Inc. for allegedly making materially false and misleading statements regarding consumer data sharing with third-party advertising platforms, charging for prescriptions before medical consultations, and failing to disclose regulatory scrutiny and potential penalties. The lead plaintiff deadline is November 2, 2026.
10/02/2026, 2:41 PM • GlobeNewswire
Kaplan Fox has filed a securities class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS) on behalf of investors who purchased securities between August 4, 2025 and July 29, 2026. The FTC sued the company for allegedly failing to disclose immediate prescription charges, making subscription cancellations difficult, and sharing consumers' health information with third-party advertising platforms like Meta and Snap. The stock fell 14.73% to $25.00 per share following the FTC action. The lead plaintiff deadline is November 2, 2026.
10/02/2026, 11:00 AM • GlobeNewswire
Schall, Brown & Schwartz LLP announces a securities fraud class action lawsuit against Hims & Hers Health, Inc. for making false and misleading statements regarding customer health data sharing with third-party advertising platforms and treatment practices that could trigger regulatory scrutiny. The class period spans August 4, 2025 to July 29, 2026, with a November 2, 2026 deadline for investors to participate.
10/02/2026, 9:54 AM • GlobeNewswire
Robbins Geller Rudman & Dowd LLP announced a class action lawsuit against Hims & Hers Health, Inc. following FTC allegations that the telehealth provider shared consumers' sensitive health information with third-party advertising platforms including Meta and Snap, and engaged in deceptive billing practices. The lawsuit covers securities purchased between August 4, 2025 and July 29, 2026, with a lead plaintiff deadline of November 2, 2026. Hims & Hers shares declined nearly 15% following the FTC announcement.
10/02/2026, 6:50 AM • GlobeNewswire
Law Offices of Howard G. Smith has filed securities fraud class action lawsuits against four publicly-traded companies: Hyliion Holdings Corp., Hims & Hers Health Inc., Unicycive Therapeutics Inc., and Baidu Inc. The lawsuits allege that defendants made materially false and misleading statements and failed to disclose material adverse facts about their respective businesses. Investors have until specified deadlines in late October and November 2026 to file lead plaintiff motions.
10/01/2026, 4:00 PM • GlobeNewswire
Hims & Hers Health faces a securities class action lawsuit after the FTC alleged the telehealth provider shared consumers' sensitive health information with third-party advertising platforms and engaged in deceptive billing practices. The stock fell 14.73% to $25.00 on July 29, 2026, following the FTC announcement. Investors with losses exceeding $100,000 have until November 2, 2026 to file lead plaintiff applications.
09/30/2026, 11:49 PM • GlobeNewswire
Hims & Hers Health (HIMS) faces a securities class action lawsuit following an FTC complaint alleging the company shared consumers' health data with third-party advertisers like Meta and Snap, charged for prescriptions before medical consultations, and violated ROSCA regulations. The stock dropped 14.7% on July 29, 2026, erasing over $970 million in market value. Investors with substantial losses are encouraged to participate in the class action.
09/30/2026, 10:59 AM • GlobeNewswire
Hims & Hers Health faces a securities fraud class action lawsuit after the FTC alleged the telehealth provider shared consumers' sensitive health information with third-party advertisers while claiming to maintain privacy, and deceived users about billing and cancellation practices. The stock declined 14.73% on July 29, 2026, following the FTC announcement. Investors who purchased securities between August 4, 2025 and July 29, 2026 have until November 2, 2026 to file lead plaintiff applications.
09/29/2026, 10:01 PM • GlobeNewswire
Peers
Statistics
MoreInformation as of 10/22/2026
Company Profile
Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, Australia, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, skincare, sexual health and wellness, and hair care under the Hims & Hers brand name; and laboratory testing services to measure a set of biomarkers. Additionally, it offers medical consultation, post-consultation support services, and delivery of laboratory testing results services. Further, the company provides treatments and products for various chronic conditions related to hormone health, weight loss, dermatology, and mental health. The company offers its products through retail partnerships, in stores, and online. The company was formerly known as Hims, Inc. and changed its name to Hims & Hers Health, Inc. in January 2021. The company was founded in 2017 and is based in San Francisco, California.